Cargando…
GAD65 Antibody-Associated Epilepsy
Autoimmune processes are an increasingly recognized cause of seizures. Antibodies against neuronal surface antigens are implicated in the development of acute symptomatic seizures secondary to autoimmune encephalitis, whereas antibodies against intracellular antigens (anti-glutamic acid decarboxylas...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10305176/ https://www.ncbi.nlm.nih.gov/pubmed/37374339 http://dx.doi.org/10.3390/medicina59061135 |
_version_ | 1785065671718076416 |
---|---|
author | Valinčiūtė, Justina Jucevičiūtė, Neringa Balnytė, Renata Jurkevičienė, Giedrė Gelžinienė, Giedrė |
author_facet | Valinčiūtė, Justina Jucevičiūtė, Neringa Balnytė, Renata Jurkevičienė, Giedrė Gelžinienė, Giedrė |
author_sort | Valinčiūtė, Justina |
collection | PubMed |
description | Autoimmune processes are an increasingly recognized cause of seizures. Antibodies against neuronal surface antigens are implicated in the development of acute symptomatic seizures secondary to autoimmune encephalitis, whereas antibodies against intracellular antigens (anti-glutamic acid decarboxylase (GAD) and onconeural antibodies) are found in cases of autoimmune-associated epilepsy (AAE). AAE is described as isolated drug-resistant epilepsy without any specific magnetic resonance imaging (MRI) or cerebrospinal fluid changes and with a very limited response to immunotherapy. We present a clinical case and a literature review on autoimmune-associated epilepsy to increase awareness of this disease and illustrate its complexity. This is a clinical case of a female with a history of refractory focal epilepsy. The patient had been given several trials of multiple antiepileptic drugs and their combinations without any clear effect. Multiple evaluations including brain MRI, PET, and interictal and ictal electroencephalograms were performed. An APE2 score was calculated with a result of 4 and, in the presence of anti-GAD65 antibodies in the serum, the diagnosis of AAE was confirmed. There was no effect after five sessions of plasma exchange; however, after a course of intravenous immunoglobulin, a positive but temporary clinical effect was noticed: anti-GAD65 levels initially decreased but rebounded to previous levels 6 months later. |
format | Online Article Text |
id | pubmed-10305176 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-103051762023-06-29 GAD65 Antibody-Associated Epilepsy Valinčiūtė, Justina Jucevičiūtė, Neringa Balnytė, Renata Jurkevičienė, Giedrė Gelžinienė, Giedrė Medicina (Kaunas) Case Report Autoimmune processes are an increasingly recognized cause of seizures. Antibodies against neuronal surface antigens are implicated in the development of acute symptomatic seizures secondary to autoimmune encephalitis, whereas antibodies against intracellular antigens (anti-glutamic acid decarboxylase (GAD) and onconeural antibodies) are found in cases of autoimmune-associated epilepsy (AAE). AAE is described as isolated drug-resistant epilepsy without any specific magnetic resonance imaging (MRI) or cerebrospinal fluid changes and with a very limited response to immunotherapy. We present a clinical case and a literature review on autoimmune-associated epilepsy to increase awareness of this disease and illustrate its complexity. This is a clinical case of a female with a history of refractory focal epilepsy. The patient had been given several trials of multiple antiepileptic drugs and their combinations without any clear effect. Multiple evaluations including brain MRI, PET, and interictal and ictal electroencephalograms were performed. An APE2 score was calculated with a result of 4 and, in the presence of anti-GAD65 antibodies in the serum, the diagnosis of AAE was confirmed. There was no effect after five sessions of plasma exchange; however, after a course of intravenous immunoglobulin, a positive but temporary clinical effect was noticed: anti-GAD65 levels initially decreased but rebounded to previous levels 6 months later. MDPI 2023-06-12 /pmc/articles/PMC10305176/ /pubmed/37374339 http://dx.doi.org/10.3390/medicina59061135 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Case Report Valinčiūtė, Justina Jucevičiūtė, Neringa Balnytė, Renata Jurkevičienė, Giedrė Gelžinienė, Giedrė GAD65 Antibody-Associated Epilepsy |
title | GAD65 Antibody-Associated Epilepsy |
title_full | GAD65 Antibody-Associated Epilepsy |
title_fullStr | GAD65 Antibody-Associated Epilepsy |
title_full_unstemmed | GAD65 Antibody-Associated Epilepsy |
title_short | GAD65 Antibody-Associated Epilepsy |
title_sort | gad65 antibody-associated epilepsy |
topic | Case Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10305176/ https://www.ncbi.nlm.nih.gov/pubmed/37374339 http://dx.doi.org/10.3390/medicina59061135 |
work_keys_str_mv | AT valinciutejustina gad65antibodyassociatedepilepsy AT juceviciuteneringa gad65antibodyassociatedepilepsy AT balnyterenata gad65antibodyassociatedepilepsy AT jurkevicienegiedre gad65antibodyassociatedepilepsy AT gelzinienegiedre gad65antibodyassociatedepilepsy |